Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 61-72 of 212 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 61-72 of 212 studies
-
ObservationalClosed to Enrollment
Phase 4 study to monitor the susceptibility of Pseudomonas aeruginosa to aztreonam in people with CF , protocol number Gilead GS-US-205-0128This 5-year study took place at multiple care centers across the U.S. It investigated the susceptibility of Pseudomonas aeruginosa isolates to the anti-infective drug aztreonam.
-
Age:
1 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
Less than 90%
-
Number of Visits:
5
-
Length of Participation:
5 years
-
-
ObservationalClosed to Enrollment
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis , protocol number NARKEW07A0This study will look at whether using abdominal ultrasounds predicts the progression of liver disease in children with CF.
-
Age:
3 Years to 12 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
5 years
-
-
OtherClosed to Enrollment
Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
49 days
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-445 Triple Combination in Teens and Adults With Cystic Fibrosis (CF) Who Have One Copy of F508del and One Copy of a Gating or Residual Function Mutation , protocol number Vertex VX18-445-104This study evaluated the safety and effectiveness of VX-445 (elexacaftor), tezacaftor, and ivacaftor in combination called TRIKAFTA®. This study was for people with CF 12 years and older with one copy of the F508del mutation and one copy of a gating or residual function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-445 triple combination in children 6-11 years old with cystic fibrosis , protocol number Vertex VX18-445-106This study evaluated the safety and effectiveness of the triple combination modulator therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®) in children ages 6-11 years with CF, who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
9
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
Roll-over study of ivacaftor in children with CF who have a CFTR gating mutation , protocol number Vertex VX-770-109This study evaluated the long-term safety of ivacaftor (Kalydeco®) in children with CF. This study was for children who have a CFTR gating mutation and received at least one dose of ivacaftor in the VX11-770-108 study.
-
Age:
2 Years to 5 Years
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
7
-
Length of Participation:
88 weeks
-
-
Restore CFTR ProteinCompleted with Results
Open-label study of ivacaftor in people with CF who have a non-G551D CFTR gating mutation , protocol number Vertex VX-770-112This study evaluated the long-term safety of ivacaftor (Kalydeco®) in participants who have a non-G551D CFTR gating mutation. This study was for people who had participated in one of the VX11-770-110, VX12-770-111, or VX12-770-113 studies.
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
7
-
Length of Participation:
2 years
-
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of PTI-808 triple-combination therapy in adults with cystic fibrosis who have at least one copy of the F508del mutation , protocol number PTI-808-01This study evaluated the effectiveness and safety of the drug, PTI-808 in combination with PTI-801, with or without PTI-428. This study was for people with CF ages 18 and older who have at least one copy of the F508del CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
9
-
Length of Participation:
10 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study to evaluate VX-121 in adults 18 years and older with cystic fibrosis , protocol number Vx-121-101 (VX18-121-101)This study evaluated the safety, tolerability, and effectiveness of three different doses of the drug VX-121 in triple combination with tezacaftor (TEZ) and VX-561 (deuterated ivacaftor) in people with cystic fibrosis who have two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
17 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study to evaluate VX-561 in adults 18 years and older with cystic fibrosis , protocol number Vertex VX-561-101This study evaluated different doses of the drug VX-561 to determine safety and effectiveness.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
8
-
Length of Participation:
16 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of ivacaftor in babies 12-24 month old who have a CFTR gating mutation , protocol number Vertex VX15-770-124This study evaluated the safety of ivacaftor (Kalydeco®) as well as how the body processes the drug in babies who have at least one copy of a CFTR gating mutation.
-
Age:
12 Months to 24 Months
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
24 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of PTI-428 drug in people with CF ages 18 and older who have two copies of the F508del CFTR mutation , protocol number Proteostasis PTI-428-06This study evaluated the safety and tolerability of the drug PTI-428. This study was for people with CF ages 18 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor/ivacaftor (Symdeko®). A key goal of the study was to determine if PTI-428 could increase the amount of CFTR protein produced in people who were already taking tezacaftor/ivacaftor (Symdeko®).
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
74 days
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More